Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

carcinoembryonic antigen peptide 1

A nine amino acid peptide fragment of carcinoembryonic antigen (CEA), a protein that is overexpressed in several cancer cell types, including gastrointestinal, breast, and non-small cell lung. Autologous vaccination with activated autologous dendritic cells (DC) or peripheral blood mononuclear cells (PBMC) which have been exposed to CEA peptide 1 in vitro may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells expressing CEA, thereby inhibiting tumor growth.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	CAP-1 Carcinoembryonic Antigen Peptide-1 Carcinoembryonic Peptide-1 CEA Peptide 1 CEA Peptide 9-mer
IND number:	6843
NSC code:	672683

carcinoembryonic antigen peptide 1

Search NCI's Drug Dictionary